Can We Design a Nogo Receptor-Dependent Cellular Therapy to Target MS?

The current landscape of therapeutics designed to treat multiple sclerosis (MS) and its pathological sequelae is saturated with drugs that modify disease course and limit relapse rates. While these small molecules and biologicals are producing profound benefits to patients with reductions in annuali...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Min Joung, Kang, Jung Hee, Theotokis, Paschalis, Grigoriadis, Nikolaos, Petratos, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357095/
https://www.ncbi.nlm.nih.gov/pubmed/30577457
http://dx.doi.org/10.3390/cells8010001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357095/
https://www.ncbi.nlm.nih.gov/pubmed/30577457
http://dx.doi.org/10.3390/cells8010001

Ejemplares similares